Peter R Gibson1, Carolynne Vaizey2, Christopher M Black3, Rebecca Nicholls4, Adèle R Weston5, Peter Bampton6, Miles Sparrow7, Ian C Lawrance8, Warwick S Selby9, Jane M Andrews10, Alissa J Walsh11, David J Hetzel12, Finlay A Macrae13, Gregory T Moore14, Martin D Weltman15, Rupert W Leong16, Tao Fan17. 1. Alfred Hospital, Australia; Monash University, Clayton, Victoria, Australia. Electronic address: Peter.Gibson@monash.edu. 2. St. Mark's Hospital, London, United Kingdom. Electronic address: cvaizey@nhs.net. 3. St. John's University, Queens, New York, USA; Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA. Electronic address: christopher.black2@merck.com. 4. OptumInsight, Sydney, New South Wales, Australia. Electronic address: Rebecca.Nicholls@optum.com. 5. OptumInsight, Sydney, New South Wales, Australia. Electronic address: adele.weston@optum.com. 6. Flinders Private Hospital, Bedford Park, Southern Australia, Australia. Electronic address: peter.bampton@flinders.edu.au. 7. Alfred Hospital, Australia. Electronic address: M.Sparrow@alfred.org.au. 8. Centre for Inflammatory Bowel Diseases, School of Medicine and Pharmacology, University of Western Australia, Fremantle Hospital, Fremantle, Western Australia, Australia. Electronic address: ian.lawrance@uwa.edu.au. 9. Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; University of Sydney, Sydney, New South Wales, Australia. Electronic address: warwicks@sydney.edu.au. 10. IBD Service, Department of Gastroenterology & Hepatology, Royal Adelaide Hospital, Adelaide, South Australia, Australia; School of Medicine, University of Adelaide, Adelaide, South Australia, Australia. Electronic address: Jane.Andrews@health.sa.gov.au. 11. St. Vincent's Hospital, Sydney, New South Wales, Australia. Electronic address: alissa.walsh@gmail.com. 12. East Adelaide Medical Centre, Adelaide, Southern Australia, Australia. Electronic address: David.Hetzel@health.sa.gov.au. 13. Royal Melbourne Hospital, Parkville, Victoria, Australia. Electronic address: Finlay.Macrae@mh.org.au. 14. Monash University, Clayton, Victoria, Australia; Monash Medical Centre, Clayton, Victoria, Australia. Electronic address: gregory.moore@monash.edu. 15. Nepean Hospital, University of Sydney, Sydney, New South Wales, Australia. Electronic address: Martin.Weltman@swahs.health.nsw.gov.au. 16. Concord Hospital, Sydney, New South Wales, Australia. Electronic address: rupertleong@unsw.edu.au. 17. Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA. Electronic address: tao_fan@merck.com.
Abstract
BACKGROUND & AIMS: The burden of ulcerative colitis (UC) in relation to disease severity is not well documented. This study quantitatively evaluated the relationship between disease activity and quality of life (QoL), as well as health care utilization, cost, and work-related impairment associated with UC in an Australian population. METHODS: A cross-sectional, noninterventional, observational study was performed in patients with a wide range of disease severity recruited during routine specialist consultations. Evaluations included the Assessment of Quality of Life-8-dimension (AQoL-8D), EuroQol 5-dimension, 5-level (EQ-5D-5L), the disease-specific Inflammatory Bowel Disease Questionnaire (IBDQ), and the Work Productivity and Activity Impairment (WPAI) instrument. The 3-item Partial Mayo Score was used to assess disease severity. Health care resource utilization was assessed by chart review and patient questionnaires. RESULTS: In 175 patients, mean (SD) AQoL-8D and EQ-5D-5L scores were greater for patients in remission (0.80 [0.19] and 0.81 [0.18], respectively) than for patients with active disease (0.70 [0.20] and 0.72 [0.19], respectively, both Ps<0.001). IBDQ correlated with both AQoL-8D (r=0.73; P<0.0001) and EQ-5D-5L (0.69; P<0.0001). Mean 3-month UC-related health care cost per patient was AUD $2914 (SD=$3447 [mean for patients in remission=$1970; mild disease=$3736; moderate/severe disease=$4162]). Patients in remission had the least work and activity impairment. CONCLUSIONS: More severe UC disease was associated with poorer QoL. Substantial health care utilization, costs, and work productivity impairments were found in this sample of patients with UC. Moreover, greater disease activity was associated with greater health care costs and impairment in work productivity and daily activities.
BACKGROUND & AIMS: The burden of ulcerative colitis (UC) in relation to disease severity is not well documented. This study quantitatively evaluated the relationship between disease activity and quality of life (QoL), as well as health care utilization, cost, and work-related impairment associated with UC in an Australian population. METHODS: A cross-sectional, noninterventional, observational study was performed in patients with a wide range of disease severity recruited during routine specialist consultations. Evaluations included the Assessment of Quality of Life-8-dimension (AQoL-8D), EuroQol 5-dimension, 5-level (EQ-5D-5L), the disease-specific Inflammatory Bowel Disease Questionnaire (IBDQ), and the Work Productivity and Activity Impairment (WPAI) instrument. The 3-item Partial Mayo Score was used to assess disease severity. Health care resource utilization was assessed by chart review and patient questionnaires. RESULTS: In 175 patients, mean (SD) AQoL-8D and EQ-5D-5L scores were greater for patients in remission (0.80 [0.19] and 0.81 [0.18], respectively) than for patients with active disease (0.70 [0.20] and 0.72 [0.19], respectively, both Ps<0.001). IBDQ correlated with both AQoL-8D (r=0.73; P<0.0001) and EQ-5D-5L (0.69; P<0.0001). Mean 3-month UC-related health care cost per patient was AUD $2914 (SD=$3447 [mean for patients in remission=$1970; mild disease=$3736; moderate/severe disease=$4162]). Patients in remission had the least work and activity impairment. CONCLUSIONS: More severe UC disease was associated with poorer QoL. Substantial health care utilization, costs, and work productivity impairments were found in this sample of patients with UC. Moreover, greater disease activity was associated with greater health care costs and impairment in work productivity and daily activities.
Authors: Aaron Yarlas; Martha Bayliss; Joseph C Cappelleri; Stephen Maher; Andrew G Bushmakin; Lea Ann Chen; Alireza Manuchehri; Paul Healey Journal: Qual Life Res Date: 2017-08-28 Impact factor: 4.147
Authors: Ioannis E Koutroubakis; Claudia Ramos-Rivers; Miguel Regueiro; Efstratios Koutroumpakis; Benjamin Click; Robert E Schoen; Jana G Hashash; Marc Schwartz; Jason Swoger; Leonard Baidoo; Arthur Barrie; Michael A Dunn; David G Binion Journal: Clin Gastroenterol Hepatol Date: 2015-04-08 Impact factor: 11.382
Authors: Michael D Mandel; Mandel D Michael; Anita Bálint; Barbara D Lovász; László Gulácsi; Bálint Strbák; Petra A Golovics; Klaudia Farkas; Zsuzsanna Kürti; Blanka K Szilágyi; Anna Mohás; Tamás Molnár; Péter L Lakatos Journal: Eur J Health Econ Date: 2014-05-16
Authors: Axel Dignass; Robert Schnabel; Jacek Romatowski; Vladimir Pavlenko; Andrey Dorofeyev; Jelena Derova; Laimas Jonaitis; Karin Dilger; Tanju Nacak; Roland Greinwald Journal: United European Gastroenterol J Date: 2017-03-30 Impact factor: 4.623
Authors: Aaron Yarlas; Stephen Maher; Martha Bayliss; Andrew Lovley; Joseph C Cappelleri; Andrew G Bushmakin; Marco D DiBonaventura Journal: J Patient Cent Res Rev Date: 2020-04-27